Eligibility Module

Eligibility Module

The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.

Eligibility Module path is as follows:

Study -> Protocol Section -> Eligibility Module

Eligibility Module


Ignite Creation Date: 2025-12-24 @ 4:32 PM
Ignite Modification Date: 2025-12-24 @ 4:32 PM
NCT ID: NCT03715166
Eligibility Criteria: Inclusion Criteria: * Male and female patients from 7 to less than 18 years * Out patients * Primary diagnosis of ASD as per Diagnostic and Statistical Manual of Mental Disorders - Fifth Edition (DSM-5) criteria * Criteria met for ASD on Autism Diagnostic Observation Schedule (ADOS-2) and Autism Diagnosis Interview Revised (ADI-R) * CGI (Clinical Global Impression) - Severity rating Score ≥ 4 * Childhood Autism Rating Scale second edition (CARS2-ST or HF) total raw score ≥ 34 * Social responsiveness Scale second edition total score (SRS-2 T-Score) ≥ 66 * Absence of known monogenic syndrome (Fragile X, Rett syndrome ...) * Absence of any clinically significant abnormality likely to interfere with the conduct of the study according to the judgment of the investigator Exclusion Criteria: * Patients not able to follow the study assessments defined by the protocol, with the exception of self-rating questionnaires which will be assessed by parent/legal representative/caregiver for those patients unable to complete them * Patients having a high suicidal risk according to the investigator judgement * Chronic renal dysfunction * Chronic cardiac dysfunction * Patient with unstable psychotherapy, behavioural, cognitive or cognitive-behavioural therapy * Severe electrolyte imbalance that is likely to interfere with the study conduct or evaluation
Healthy Volunteers: False
Sex: ALL
Minimum Age: 7 Years
Maximum Age: 17 Years
Study: NCT03715166
Study Brief:
Protocol Section: NCT03715166